Trial reportFrontiers in medicine2025
Integration of Ayurveda in managing chemotherapy-induced hand-foot-skin reaction-an exploratory quasi experimental study.
Trial report in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hand-foot-skin reaction (HFSR) is one of the major mucocutaneous adverse events of multi-kinase inhibitors (MKIs). Its overall incidence is 35.0%. It negatively impacts the quality of life of the patient and compliance with chemotherapy. Present management of HFSR is largely anecdotal, and the common treatment is dose regulation or discontinuation of chemotherapy. In Ayurveda, the clinical presentation of HFSR may be understood as Methodology: This is a double-arm-controlled interventional study with a quasi-experimental design, registered in the Clinical Trial Registry of India under CTRI/2022/03/040929, with 22 participants from the Medical Oncology Department and Integrative Medicine, Amrita Institute of Medical Sciences, Kochi. The study group received an add-on treatment to the standard of care (SOC). This included Results and conclusion: The study group demonstrated a significant reduction in pain (VAS) and improvement in quality of life (HF-QoL) compared to the control group. Clinical trial registration: CTRI/2022/03/040929, https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjMwMTE=&Enc=&userName=.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.